Catch up on this week's highlights in retina.

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease.

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.

Ocular Therapeutix showcases innovative TKI treatments for retinal diseases at the Clinical Trials Summit in Las Vegas, June 21, 2025.

Looking at innovative tools and their applications in different disease states can help to think creatively about ways to benefit patients in retina care.

Ainnova has collaborated with leading pharmacies to offer free diabetic retinopathy screenings to patients with diabetes.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Investigators take an in-depth look at all aspects of the technology.

A mutation-agnostic gene therapy approach offers new possibilities for patients with advanced retinal disease.

The report highlights clinical successes, innovation, research, and patient outcomes.

Catch up on this week's highlights in retina.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the development of vision restoration therapies.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.

Catch up on this week's highlights in retina.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.